- Directors Joseph A. Madri and Larry L. Mathis to Retire in May 2014 -
CHESHIRE, Conn.--(BUSINESS WIRE)--
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced the
appointment of John "Jack" T. Mollen to the Company's Board of
Directors, effective immediately. The Company also announced that Joseph
A. Madri, Ph.D., M.D. and Larry L. Mathis, will retire at the conclusion
of the current term on May 5, 2014, after 22 years and 10 years of
service to the Company, respectively.
"Jack has a remarkable track record as a leader and executive and brings
substantial operational experience in human resources and organizational
development to the Alexion Board. His expertise will be valuable to our
growing global organization and we are pleased to welcome him to the
Alexion Board of Directors," said Max Link, Ph.D. Chairman of Alexion's
Board of Directors.
Jack Mollen was most recently special advisor to the Chairman of EMC
Corporation and previously served as EMC's Executive Vice President,
Human Resources (HR) for 14 years. While at EMC, Mr. Mollen led the
global human resources function to ensure the availability of
world-class talent to drive business success and his responsibilities
included executive, leadership, and employee development; compensation
and benefits; staffing; and all of the people-related aspects of
acquisition integration. Prior to joining EMC, Mr. Mollen was Vice
President of Human Resources at Citigroup Inc. Mr. Mollen serves as a
director for a number of not-for-profit and professional boards,
including the New England Healthcare Institute, the HR Policy
Association, Center on Executive Compensation, Worcester Polytechnic
Institute Board of Trustees and Chairman of its Compensation Committee,
and as an advisory board member for Working Mother magazine. Mr.
Mollen received a bachelor's degree in economics from St. John Fisher
College in Rochester, N.Y., and a master's degree in labor relations
from St. Francis University in Loretto, Pa.
"I am honored to join Alexion's Board of Directors at this exciting time
in the Company's continuing global expansion. I look forward to playing
an integral role that will contribute to the fulfillment of Alexion's
unique mission to develop and deliver innovative therapies for patients
with severe and life-threatening rare diseases," said Mr. Mollen.
Alexion also announced the retirement of two long-standing directors who
have each made invaluable contributions to the Company's growth and
global expansion during a combined 32 years of service.
Joseph A. Madri, M.D., Ph.D., who has been a director since the
Company's founding in 1992, is retiring from the Board after 22 years of
outstanding service to Alexion. Dr. Madri has been on the faculty of the
Yale University School of Medicine since 1980, and is currently a
professor of pathology and molecular, cellular and developmental
biology. Dr. Madri also serves on the editorial boards of numerous
scientific journals and is the author of over 243 scientific
publications. "Joe has served on Alexion's Board with distinction and we
are grateful for his significant contributions to research and
scientific dialog and his dedicated tenure with Alexion," said Leonard
Bell, M.D., Chief Executive Officer of Alexion Pharmaceuticals.
In addition, Larry L. Mathis is also retiring from the Board after a
decade of outstanding service to the Company. Since 1998 he has served
as an executive consultant with D. Peterson & Associates in Houston,
providing counsel on leadership, management, governance and strategy.
Mr. Mathis was the founding president and chief executive officer of The
Methodist Hospital System in Houston, having served that institution in
various executive positions for 27 years, including 14 years as Chief
Executive Officer before his retirement in 1997. "Larry has been an
excellent Board member and we are thankful for his commitment to the
highest standards of corporate governance on Alexion's Board as well as
his business insights in the healthcare industry," said Dr. Bell.
About Alexion
Alexion is a biopharmaceutical company focused on serving patients with
severe and rare disorders through the innovation, development and
commercialization of life-transforming therapeutic products. Alexion is
the global leader in complement inhibition and has developed and markets
Soliris® (eculizumab) as a treatment for patients with PNH
and aHUS, two debilitating, ultra-rare and life-threatening disorders
caused by chronic uncontrolled complement activation. Soliris is
currently approved in nearly 50 countries for the treatment of PNH, and
in the United States, European Union, Japan and other countries for the
treatment of aHUS. Alexion is evaluating other potential indications for
Soliris in additional severe and ultra-rare disorders beyond PNH and
aHUS, and is developing other highly innovative biotechnology product
candidates across multiple therapeutic areas. This press release and
further information about Alexion Pharmaceuticals can be found at: www.alexionpharma.com.
[ALXN-G]
Alexion Pharmaceuticals, Inc.
Irving Adler, 203-271-8210
Executive
Director, Corporate Communications
or
(Media)
Kim
Diamond, 203-439-9600
Senior Director, Corporate Communications
or
(Investors)
Rx
Communications
Rhonda Chiger, 917-322-2569
Source: Alexion Pharmaceuticals, Inc.
News Provided by Acquire Media